<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735993</url>
  </required_header>
  <id_info>
    <org_study_id>CREATE</org_study_id>
    <nct_id>NCT02735993</nct_id>
  </id_info>
  <brief_title>Cardiac REgistry of Celution Device for the Processing of Adipose-derived Regenerative Cells</brief_title>
  <acronym>CREATE</acronym>
  <official_title>Cardiac REgistry of Celution Device for the Processing of Adipose-derived Regenerative Cells: Treatment and Evaluation (CREATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytori Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytori Therapeutics</source>
  <brief_summary>
    <textblock>
      This cardiac registry study will collect information from patients with ischemic or
      non-ischemic heart failure that have been treated with adipose-derived regenerative cells
      (ADRCs) delivered via intramyocardial injection.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Corporate decision
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Change in the Minnesota Living with Heart Failure Questionnaire.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Symptoms</measure>
    <time_frame>Days 90, 180 and 360</time_frame>
    <description>Heart Failure Symptoms as assessed by New York Heart Association (NYHA) Functional Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVESV/LVEDV</measure>
    <time_frame>Day 180</time_frame>
    <description>Left ventricular function assessed by contrast Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF assessed by contrast Echocardiography</measure>
    <time_frame>Day 180</time_frame>
    <description>Left ventricular function assessed by contrast Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treadmill exercise test</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina Symptoms</measure>
    <time_frame>Days 90, 180 and 360</time_frame>
    <description>Angina Symptoms as measured by Canadian Cardiovascular Society Grading System for exertion-induced angina</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MACEs defined as cardiac death, myocardial infarction or hospitalization for heart failure.</measure>
    <time_frame>Ongoing evaluation from Day 1 through Month 60</time_frame>
  </other_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with heart failure due to non-ischemic disease (idiopathic cardiomyopathy) or
        coronary artery disease (CAD) that can not be revascularized.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females &gt; 20 and &lt; 80 years of age

          -  Significant multi-vessel coronary artery disease not amenable to percutaneous or
             surgical revascularization OR idiopathic dilated cardiomyopathy

          -  Symptoms of heart failure (e.g. NYHA Stages of Heart Failure Class II or III)

          -  On maximal medical therapy for heart failure and if present, anginal symptoms

          -  Hemodynamic stability (SBP ≥ 90 mm/Hg, HR &lt;110 beats/min)

          -  Ejection fraction ≤ 45%

          -  Left ventricular wall thickness &gt; 5 mm at the target site(s) for cell injection,
             confirmed by Contrast Echo within 4 weeks prior to enrollment, and free of thrombus

        Exclusion Criteria:

          -  Vascular anatomy and/or peripheral artery disease that prevents or impedes cardiac
             catheterization

          -  Aortic or mitral valve disease where valve replacement is indicated

          -  Presence of mechanical aortic or mitral valves

          -  Presence of aortic dissection

          -  Planned staged treatment of CAD or other therapeutic intervention on the heart within
             the subsequent 3 months

          -  TIA or stroke within 30 days prior to the procedure

          -  ICD placement or ablation therapy within 30 days prior to the procedure

          -  Acute coronary syndrome (ACS) or a myocardial infarction in the 30 days prior to the
             procedure

          -  Revascularization within 30 days prior to intramyocardial injection of ADRCs

          -  Pregnant or lactating status. Pregnancy as determined by a positive pregnancy test at
             screening or baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Kesten</last_name>
    <role>Study Chair</role>
    <affiliation>Cytori Therapeutics</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Celution</keyword>
  <keyword>ADRC</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

